| Literature DB >> 31797796 |
Joshua L Owen1, Nour Kibbi2, Brandon Worley3, Ryan C Kelm1, Jordan V Wang4, Christopher A Barker5, Ramona Behshad6, Christopher K Bichakjian7, Diana Bolotin8, Jeremy S Bordeaux9, Scott H Bradshaw10, Todd V Cartee11, Sunandana Chandra12, Nancy L Cho13, Jennifer N Choi1, M Laurin Council14, Hakan Demirci15, Daniel B Eisen16, Bita Esmaeli17, Nicholas Golda18, Conway C Huang19, Sherrif F Ibrahim20, S Brian Jiang21, John Kim22, Timothy M Kuzel23, Stephen Y Lai24, Naomi Lawrence25, Erica H Lee26, Justin J Leitenberger27, Ian A Maher28, Margaret W Mann29, Kira Minkis30, Bharat B Mittal31, Kishwer S Nehal26, Isaac M Neuhaus32, David M Ozog33, Brian Petersen34, Veronica Rotemberg26, Sandeep Samant35, Faramarz H Samie36, Sabah Servaes37, Carol L Shields38, Thuzar M Shin39, Joseph F Sobanko39, Ally-Khan Somani40, William G Stebbins41, J Regan Thomas35, Valencia D Thomas42, David T Tse43, Abigail H Waldman44, Michael K Wong45, Y Gloria Xu46, Siegrid S Yu32, Nathalie C Zeitouni47, Timothy Ramsay48, Kelly A Reynolds1, Emily Poon1, Murad Alam49.
Abstract
Sebaceous carcinoma usually occurs in adults older than 60 years, on the eyelid, head and neck, and trunk. In this Review, we present clinical care recommendations for sebaceous carcinoma, which were developed as a result of an expert panel evaluation of the findings of a systematic review. Key conclusions were drawn and recommendations made for diagnosis, first-line treatment, radiotherapy, and post-treatment care. For diagnosis, we concluded that deep biopsy is often required; furthermore, differential diagnoses that mimic the condition can be excluded with special histological stains. For treatment, the recommended first-line therapy is surgical removal, followed by margin assessment of the peripheral and deep tissue edges; conjunctival mapping biopsies can facilitate surgical planning. Radiotherapy can be considered for cases with nerve or lymph node involvement, and as the primary treatment in patients who are ineligible for surgery. Post-treatment clinical examination should occur every 6 months for at least 3 years. No specific systemic therapies for advanced disease can be recommended, but targeted therapies and immunotherapies are being developed.Entities:
Year: 2019 PMID: 31797796 DOI: 10.1016/S1470-2045(19)30673-4
Source DB: PubMed Journal: Lancet Oncol ISSN: 1470-2045 Impact factor: 41.316